JCA Devices Live, Camizestrant Divergence, JSC Window Open

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: the tovorafenib JCA report and what the procedural lag means for timeline planning, medical device JCAs crossing from theory into operational reality, the JSC window that opened 1 June, and the camizestrant transatlantic split — EMA says yes, FDA says not yet. Let's get into it.

MarcusThe second completed JCA report — tovorafenib, Ojemda, paediatric brain tumour indication — was formally published on 9 June 2026. The HTACG endorsed it on 30 April, the European Commission closed its procedural review on 19 May, and it went public on the 9th. That's roughly six weeks from endorsement to public availability. If you're modelling submission-to-access timelines, that's your minimum post-endorsement lag before national HTA bodies can formally rely on the report.

SaraAnd the full developer dossier is publicly downloadable. That's the part that keeps me up at night from a competitive intelligence standpoint. Every payer, every competitor HEOR team, every reimbursement consultancy can now systematically audit the evidence framework AstraZeneca — or whoever the developer is — submitted. That ratchets up submission standards in a very direct way. You're no longer just competing against a precedent; you're competing against a published playbook.

MarcusRight, and the analyst commentary in the briefing flags exactly that. With 15 initiated JCAs now in the system and the HTACG's 2026 Annual Work Programme signalling a substantial increase in future activity, every completed report is a live PICO precedent. What I'd push back on slightly is whether that transparency is as damaging as it sounds. If your evidence generation is robust, a competitor seeing your dossier framework doesn't hurt you — it forces everyone up.

SaraThat's a reasonable point for companies with mature evidence packages. But for a developer in an adjacent indication, seeing exactly how comparators were scoped and which endpoints passed HTACG scrutiny is more than competitive intelligence — it tells you whether your current trial design is going to survive PICO construction. That's a strategic advantage that flows unevenly across the market.

MarcusFair. The practical takeaway for HEOR directors is clear: build in a minimum six to eight week post-endorsement buffer in your access timeline models, treat the tovorafenib report as precedent, and your clinical team should be auditing that dossier if they haven't already.

SaraAnd if they haven't downloaded it yet, that's a gap.

MarcusMoving to devices. This is now confirmed: medical device JCAs are operationally live as of June 2026. Approximately five device JCAs planned for the full year, up to 15 devices potentially in scope based on the HTACG's Emerging Health Technologies Report, and two to five device Joint Scientific Consultations planned for the year. Class IIb and Class III MDs where EMA Expert Panels have issued scientific opinions, and Class D IVDs — those are the scope parameters.

SaraWhat's alarming is the JSC uptake figure — or lack of it. Zero JSC requests from medical device or IVD developers in 2025, against planned targets. That means a substantial cohort of device manufacturers either didn't engage with the new system or actively chose to defer. And now formal assessments are beginning. That's not a cautious strategy — that's a structural evidence-gap problem arriving in real time.

MarcusI'd characterise it slightly differently. Some of that non-engagement is rational in a first year when the regulatory machine is still calibrating. If the methodology for devices isn't fully developed — and it isn't, the briefing notes explicitly that methodology gaps exist — there's a coherent argument that waiting for more settled guidance reduces the risk of being assessed under a framework that shifts underneath you.

SaraI understand the argument, but I don't buy it as risk mitigation. The devices that are in scope right now are Class IIb and III with existing EMA Expert Panel opinions. Those developers already have a regulatory touchpoint. The idea that they're deferring strategically rather than simply being unprepared — I think we should be honest that most of this is unpreparedness. MedTech companies have not built HEOR infrastructure at the level pharma has, and this is where that gap surfaces.

MarcusWe probably agree on the outcome even if we disagree on the cause. Either way, HEOR teams supporting device clients need to be running comparative clinical evidence gap analyses now. Not in Q4. Now.

SaraAnd checking whether their product falls within that IVD Class D scope — because I'd wager a meaningful number of diagnostics teams haven't mapped that yet.

MarcusThe third story is the JSC submission window that opened 1 June 2026. The European Commission opened the latest formal application period for Joint Scientific Consultations. The HTACG's 2026 Annual Work Programme anticipates eight to twelve JSCs for medicines and two to five for devices. This runs in parallel with EMA scientific advice, which is the mechanism you'd use if you want coordinated regulatory and HTA input on study design simultaneously.

SaraThe framing I'd put on this is simple: if your pivotal study design is still open — comparators not locked, primary endpoint not finalised — and you're planning to seek EU reimbursement, the cost-benefit calculation on a JSC has shifted decisively. JCA PICO complexity is already an established friction point. The JSC is the lever that lets you shape it before it shapes you.

MarcusAgreed. And the updated Q&A on JCA methodology published 18 May 2026 gives developers more operational clarity than they had a year ago. The machine is becoming more legible. That actually increases the value of JSC engagement because the advice you get is now more likely to be actionable.

SaraThere's a timing pressure here that I think gets underestimated. These windows are scheduled — they're not open on a rolling basis. If you miss this window and your trial design closes before the next one, you've lost the opportunity to align. HEOR strategy leads need to have a JSC decision on the table right now, not after the next steering committee.

MarcusHard to argue with that. Let's get into camizestrant. This is the most complex active HEOR file I've seen in quite some time. EMA CHMP adopted a positive opinion on 22 May 2026 for camizestrant in combination with a CDK4/6 inhibitor — palbociclib, ribociclib, or abemaciclib — for ER-positive, HER2-negative locally advanced or metastatic breast cancer with ESR1 mutation. FDA, on the other hand: ODAC voted 6 to 3 against the NDA on 30 April, with the FDA explicitly stating that PFS2 is not an acceptable efficacy endpoint, and noting that OS data are immature. PDUFA date extended to allow review of additional data.

SaraAnd then ASCO on 2 June. SERENA-6, third data cutoff, median follow-up 23.5 months. PFS hazard ratio of 0.45, absolute improvement of 7.6 months — 16.8 months versus 9.2 months. PFS2 met at HR 0.63. ctDNA clearance 51.0% with camizestrant versus 1.9% with aromatase inhibitor. The data are striking. And the EMA looked at essentially the same dataset and gave a positive opinion. The FDA looked at it and said not yet. That's not a minor methodological nuance — that's a fundamental divergence in what constitutes demonstrated clinical benefit.

MarcusAnd the question that matters most for this audience is what happens at NICE. The UK appraisal hasn't been scoped yet. But when it is, the committee is going to have to adjudicate between two positions from major regulators who reviewed the same evidence and reached opposite conclusions. The evidence basis will be a PFS HR in a biomarker-selected population — ESR1 mutation detected via ctDNA before radiographic progression — and a PFS2 endpoint that the FDA has explicitly rejected as a regulatory basis.

SaraHere's where I'd push back on how some manufacturers will approach this. There will be a temptation to anchor the economic model to the EMA position — positive opinion, strong PFS data, biomarker-defined population — and build the cost-utility analysis around PFS as surrogate for OS. I think that's a mistake. NICE has its own established scepticism about PFS as a surrogate in HR-positive metastatic breast cancer, and without mature OS data, the uncertainty intervals on any economic model are going to be very wide. The FDA's ODAC concerns are not going to be invisible to NICE's Evidence Review Group.

MarcusI take that point. But I'd argue the ctDNA clearance data changes the evidentiary texture of the case in a way that's more than cosmetic. Fifty-one percent ctDNA clearance versus under two percent — if you can validate that as a predictor of longer-term efficacy, it gives you something to work with in a surrogate validation analysis that goes beyond a simple PFS-to-OS extrapolation. That's not a solved problem, but it's a credible research pathway.

SaraIt's a credible pathway that requires heavy investment in surrogate endpoint validation methodology, and NICE will scrutinise it at least as hard as ODAC did. The additional complexity is that this is a switching intervention triggered by molecular detection — not conventional radiographic progression. That's a population definition question that affects both the comparator and the model structure. What's the natural history of patients treated on first-line therapy past the point of ESR1 mutation detection? That data is thin.

MarcusWe're not going to resolve that today. But the practical implication for HEOR teams building the NICE dossier — and the teams anticipating it on the payer side — is clear. Surrogate validation analysis is not optional. The uncertainty around OS is not a gap you can paper over with sensitivity analysis. And the transatlantic regulatory divergence will be in the room throughout the appraisal process.

SaraThe global picture adds another layer. Approved already in UAE and Saudi Arabia, parallel reviews in Japan. That multi-tiered access landscape for a single product is operationally rare. It means access strategy teams are managing multiple reference pricing risks simultaneously, which adds commercial complexity to an already difficult evidence situation.

MarcusAlright. Let's close out. The JCA machinery is producing output — the tovorafenib timeline is now a data point, not a projection. Devices are in scope and in motion. The JSC window is open and the case for using it has never been stronger.

SaraAnd camizestrant is a live case study in what happens when regulators diverge on the same evidence. For HEOR teams, the lesson isn't which regulator is right — it's that your economic model needs to be built for a committee that will have read both positions.

MarcusBuild for the hardest question in the room, not the easiest.

SaraThat's always been the job.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.